CAUTION: This message came from outside Imperial. Do not click links or open attachments unless you recognise the sender and were expecting this email.

Hi Franco,

In my opinion, both option 1 and option 2 are feasible, with a preference for option 2 given that the number of partners is still limited and we “need” partners (even if we should balance academic partners with other type of organisations). 
I would avoid having ICL as the lead, since you would be WP leaders for four work packages. NYU is too risky, as is WHO. Having them as WP leader would correspond to a higher budget  with a high rate.

In summary I would go for options 1 or 2

I hope this can help
Loredana 


Loredana Marmora

Il giorno 22 mar 2026, alle ore 11:56, Sassi, Franco <f.sassi@imperial.ac.uk> ha scritto:


As I had mentioned to Jack, I spoke to Wolfgang Ahrens last Friday. The call went well, he seemed interested, although he was keen to use this opportunity to do a follow up data collection on his old cohort of children, which is not very relevant to Z-HEALTH. In any case, he has just written to me to say that he has spoken to some colleagues and unfortunately could not find anyone who has the time to take this on given the short time frame. 

This leaves us with an urgent decision (or "one more" urgent decision, I should say), because we badly need a strong academic partner to lead WP3. I see the following options:
  1. Expand the role of the University of Cologne, by including their medical faculty, as Daniel has proposed at some point. I am not sure whether they have expertise to cover all three health areas, but they would be a credible partner in that role. 
  2. Seek a new academic partner. Katja has proposed the Technical University of Dresden, but for expertise that is different from what's needed to lead WP3. I would be more inclined to ask the University of Amsterdam, whom we know well and could probably move swiftly if willing to do so, or Maastricht, whom we know less well. There may be other options too. 
  3. Expand Imperial’s role. We could easily lead WP3, but it's very risky in terms of consortium balance. Or expand NYU's role, also risky in my opinion. 
  4. Make WHO lead WP3. Not an academic partner, obviously, but one that does have the technical expertise required. Making them WP leader would probably prevent the EC from disallowing the funding. 
I have to take action on this tomorrow (Monday), because time is running out. Please, let me know your views. 

Franco 


_______________________________________________
zhealth-mgmt mailing list -- zhealth-mgmt@imperial.ac.uk
To unsubscribe send an email to zhealth-mgmt-leave@imperial.ac.uk